Targeting PKCΘ in alloreactivity and graft-versus-host-disease: Unanswered questions and therapeutic potential

Frontiers in Immunology

Volumn 3, Issue AUG, 2012, Pages

  Bronk, Crystina C ^a,b   Yu, Xue Zhong ^a,c   Beg, Amer A ^a,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alloreactivity; Anti tumor effect; Graft versus host disease; Protein kinase C; T cell activation

Indexed keywords

EID: 84874221354     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00259     Document Type: Article

References (34)

1. Anderson, K., Fitzgerald, M., Dupont, M., Wang, T., Paz, N., Dorsch, M., Healy, A., Xu, Y., Ocain, T., Schopf, L., Jaffee, B., and Picarella, D. (2006). Mice deficient in PKC theta demonstrateimpairedinvivoT cell activation and protection from T cell-mediated inflammatory diseases. Autoimmunity 39,469-478.
2. Appelbaum, F. R. (2001). Haematopoi-etic cell transplantation as immuno-therapy. Nature 411,385-389.
3. Baier, G., and Wagner, J. (2009). PKC inhibitors: potential in T cell-dependent immune diseases. Curr. Opin. Cell Biol. 21,262-267.
4. Barouch-Bentov, R., Lemmens, E. E., Hu, J., Janssen, E. M., Droin, N. M., Song, J., Schoenberger, S. P., and Altman, A. (2005). Protein kinase C-theta is an early survival factor required for differentiation of effec-tor CD8+ T cells. J. Immunol. 175, 5126-5134.
5. Berg-Brown, N. N., Gronski, M. A., Jones, R. G., Elford, A. R., Deenick, E. K., Odermatt, B., Littman, D. R., and Ohashi, P. S. (2004). PKC theta signals activation versus tolerance in vivo. J. Exp. Med. 199,743-752.
6. Cole, D. C., Asselin, M., Brennan, A., Czerwinski, R., Ellingboe, J. W., Fitz, L., Greco, R., Huang, X., Joseph-McCarthy, D., Kelly, M. F., Kirisits, M., Lee, J., Li, Y., Mor-gan, P., Stock, J. R., Tsao, D. H., Wissner, A., Yang, X., and Chaudhary, D. (2008). Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKC theta) inhibitors. J. Med. Chem. 51, 5958-5963.
7. Cywin, C. L., Dahmann, G., Prokopow-icz, A. S. III, Young, E. R., Magolda, R. L., Cardozo, M. G., Cogan, D. A., Disalvo, D., Ginn, J. D., Kashem, M. A., Wolak, J. P., Homon, C. A., Far-rell, T. M., Grbic, H., Hu, H., Kaplita, P. V., Liu, L. H., Spero, D. M., Jean-favre, D. D., O'Shea, K. M., White, D. M., Woska, J. R. Jr., and Brown, M. L. (2007). Discovery of potent and selective PKC-theta inhibitors. Bioorg. Med. Chem. Lett. 17, 225-230.
8. Graff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A., Goode, R., Lewis, J. E., Sams, L., Huss, K. L., Campbell, R. M., Iversen, P. W., Neubauer, B. L., Brown, T. J., Musib, L., Geeganage, S., and Thorn-ton, D. (2005). The protein kinase Cbeta-selective inhibitor, Enzastau-rin (LY317615.HCl), suppresses sig-naling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65,7462-7469.
9. Gruber, T., Hermann-Kleiter, N., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Thuille, N., Letschka, T., Barsig, J., Baudler, M., Li, J., Metzler, B., Nüsslein-Hildesheim, B., Wagner, J., Leitges, M., and Baier, G. (2009). PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivo. Mol. Immunol. 46, 2071-2079.
10. Grumont, R., Lock, P., Mollinari, M., Shannon, F. M., Moore, A., and Gerondakis, S. (2004). The mitogen-induced increase in T cell size involves PKC and NFAT acti-vation of Rel/NF-kappaB-dependent c-myc expression. Immunity 21, 19-30.
11. Gupta, S., Manicassamy, S., Vasu, C., Kumar, A., Shang, W., and Sun, Z. (2008). Differential requirement of PKC-theta in the development and functionof naturalregulatoryTcells. Mol. Immunol. 46,213-224.
12. Healy, A. M., Izmailova, E., Fitzger-ald, M., Walker, R., Hattersley, M., Silva, M., Siebert, E., Terkelsen, J., Picarella, D., Pickard, M. D., LeClair, B., Chandra, S., and Jaffee, B. (2006). PKC-theta-deficient mice are pro-tected from Th1-dependent antigen-induced arthritis. J. Immunol. 177, 1886-1893.
13. Herbst, R. S., Oh, Y., Wagle, A., and Lahn, M. (2007). Enzastaurin, a pro-tein kinase Cbeta-selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin. Cancer Res. 13,s4641-s4646.
14. Hossain, M. S., Roback, J. D., Pol-lack, B. P., Jaye, D. L., Langston, A., and Waller, E. K. (2007). Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood 109,4548-4556.
15. Hossain, M. S., Roback, J. D., Wang, F., and Waller, E. K. (2008). Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J. Immunol. 180, 6892-6902.
16. Letschka, T., Kollmann, V., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Obermair, G. J., Fresser, F., Leitges, M., Hermann-Kleiter, N., Kaminski, S., and Baier, G. (2008). PKC-theta selectively controls the adhesion-stimulating molecule Rap1. Blood 112,4617-4627.
17. Liang, Y., Liu, C., Djeu, J. Y., Zhong, B., Peters, T., Scharffetter-Kochanek, K., Anasetti, C., and Yu, X. Z. (2007). Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood 111, 954-962.
18. Manicassamy, S., Yin, D., Zhang, Z., Molinero, L. L., Alegre, M. L., and Sun, Z. (2008). A criti-cal role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection. J. Immunol. 181, 513-520.
19. Marsland, B. J., and Kopf, M. (2008). T-cell fate and function: PKC-theta and beyond. Trends Immunol. 29, 179-185.
20. Marsland, B. J., Nembrini, C., Grun, K., Reissmann, R., Kurrer, M., Leip-ner, C., and Kopf, M. (2007). TLR ligands act directly upon T cells to restoreproliferationintheabsenceof protein kinase C-theta signaling and promoteautoimmunemyocarditis. J. Immunol. 178,3466-3473.
21. Marsland, B. J., Nembrini, C., Schmitz, N., Abel, B., Krautwald, S., Bach-mann, M. F., and Kopf, M. (2005). Innate signals compensate for the absence of PKC-Θ during in vivo CD8(+) T cell effector and mem-ory responses. Proc. Natl. Acad. Sci. U.S.A. 102,14374-14379.
22. Marsland, B. J., Soos, T. J., Spath, G., Littman, D. R., and Kopf, M. (2004). Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J. Exp. Med. 200,181-189.
23. Meyers, J. D., Flournoy, N., and Thomas, E. D. (1986). Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153,478-488.
24. Pfeifhofer, C., Kofler, K., Gruber, T., Tabrizi, N.G., Lutz, C., Maly, K., Leit-ges, M., and Baier, G. (2003). Protein kinase C theta affects Ca2+ mobi-lization and NFAT cell activation in primary mouse T cells. J. Exp. Med. 197, 1525-1535.
25. Salek-Ardakani, S., So, T., Halteman, B. S., Altman, A., and Croft, M. (2005). Protein kinase Ctheta controls Th1 cells in experimental autoimmune encephalomyelitis. J. Immunol. 175, 7635-7641.
26. Shlomchik, W. D. (2007). Graft-versus-host disease. Nat. Rev. Immunol. 7, 340-352.
27. Skvara, H., Dawid, M., Kleyn, E., Wolff, B., Meingassner, J. G., Knight, H., Dumortier, T., Kopp, T., Fallahi, N., Stary, G., Burkhart, C., Grenet, O., Wagner, J., Hijazi, Y., Morris, R. E., McGeown, C., Rordorf, C., Griffiths, C. E. M., Stingl, G., and Jung, T. (2008). The PKC inhibitor AEB071 may be a therapeutic option for pso-riasis. J. Clin. Invest. 118, 3151-3159.
28. Sun, Z., Arendt, C. W., Ellmeier, W., Schaeffer, E. M., Sunshine, M. J., Gandhi, L., Annes, J., Petrzilka, D., Kupfer, A., Schwartzberg, P. L., and Littman, D. R. (2000). PKC-theta is required for TCR-induced NF-kappaB activation in mature but notimmatureTlymphocytes. Nature 404,402-407.
29. Sutcliffe, E. L., Bunting, K. L., He, Y. Q., Li, J., Phetsouphanh, C., Sed-diki, N., Zafar, A., Hindmarsh, E. J., Parish, C. R., Kelleher, A. D., McInnes, R. L., Taya, T., Milburn, P. J., and Rao, S. (2011). Chromatin-associated protein kinase C-Θ reg-ulates an inducible gene expression programandmicroRNAsinhumanT lymphocytes. Mol. Cell 41, 704-719.
30. Valenzuela, J. O., Iclozan, C., Hossain, M. S., Prlic, M., Hopewell, E., Bronk, C. C., Wang, J., Celis, E., Engelman, R. W., Blazar, B. R., Bevan, M. J., Waller, E. K., Yu, X. Z., and Beg, A. A. (2009). PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J. Clin. Invest. 119,3774-3786.
31. Welniak, L. A., Blazar, B. R., and Murphy, W. J. (2007). Immuno-biology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25, 139-170.
32. Zanin-Zhorov, A., Ding, Y., Kumari, S., Attur, M., Hippen, K. L., Brown, M., Blazar, B. R., Abramson, S. B., Lafaille, J.J.,andDustin, M.L.(2010). Protein kinase C-theta mediates neg-ative feedback on regulatory T cell function. Science 328, 372-376.
33. Zanin-Zhorov, A., Dustin, M. L., and Blazar, B. R. (2011). PKC-theta func-tion at the immunological synapse: prospects for therapeutic targeting. Trends Immunol. 32,358-363.
34. Zheng, Y., Vig, M., Lyons, J., Van Parijs, L., and Beg, A. A. (2003). Combined deficiencyofp50andcRelinCD4+T cells reveals an essential requirement for NF-kB in regulating mature T cell survival and in vivo function. J. Exp. Med. 197, 861-874.